NCT00843310View on ClinicalTrials.gov

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide (Revlimid)

DRUG

Melphalan

DRUG

Dexamethasone

Trial Locations (3)

10016

Bellevue Hospital, New York

NYU Cancer Center, New York

NYU Tisch Hospital, New York

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

NYU Langone Health

OTHER